Insider Transactions in Q3 2021 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2021
|
Lawrence Otto Klein CBO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-38.07%
|
$492,219
$117.86 P/Share
|
|
Sep 13
2021
|
James R. Kasinger General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,741
-13.98%
|
$554,697
$117.86 P/Share
|
|
Sep 10
2021
|
Lawrence Otto Klein CBO & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+47.51%
|
-
|
|
Sep 10
2021
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+22.77%
|
-
|
|
Sep 01
2021
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
787
-0.42%
|
$97,588
$124.83 P/Share
|
|
Aug 06
2021
|
Michael John Tomsicek Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-73.35%
|
$3,450,000
$138.84 P/Share
|
|
Aug 06
2021
|
Michael John Tomsicek Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+48.18%
|
$425,000
$17.75 P/Share
|
|
Aug 05
2021
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,500
-2.76%
|
$3,648,000
$128.73 P/Share
|
|
Aug 05
2021
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,500
+11.65%
|
$342,000
$12.57 P/Share
|
|
Aug 04
2021
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.79%
|
$187,500
$125.02 P/Share
|
|
Aug 04
2021
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.79%
|
$18,000
$12.57 P/Share
|
|
Jul 19
2021
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
10,000
-1.61%
|
$1,270,000
$127.04 P/Share
|